YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT
PASSING OF CONSISTENCY EVALUATION FOR OSELTAMIVIR PHOSPHATE CAPSULE

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company's oseltamivir phosphate capsule (75mg) (the "**Drug**") has been granted approval by the National Medical Products Administration for passing the consistency of quality and efficacy evaluation of generic drugs (the "**Consistency Evaluation**").

Oseltamivir phosphate capsule (Brand name: Kewei) is one of the key products of the Company. Oseltamivir phosphate is a first-line treatment for influenza recommended by the National Health Commission of the PRC and is suitable for high-risk patients or suspected cases with severe symptoms, and was included in the National Essential Drug List in 2018. The Company's product Kewei is the single brand with the largest market share of oseltamivir phosphate in the China market. The successful passing of the Consistency Evaluation of the Drug is an authoritative reaffirmation of the Company's research and development capabilities, production and drug quality and drug efficacy, and allows the Drug to gain advantage in aspects such as market expansion and medical insurance payment in the future. The Group will continue to promote the Consistency Evaluation of other generic drugs and provide a medication option of both good quality and competitive price for patients.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
20 February 2019

As of the date of this announcement, the Board of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. FU Hailiang and Mr. LEE Chi Ming as independent non-executive directors.